Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives $9.83 Average Price Target from Analysts

Key Points

• Treace Medical Concepts, Inc. (NASDAQ:TMCI) maintains a consensus rating of "Hold" from six brokerages, with an average 12-month price target set at $9.83.
• Institutional investors currently hold 84.08% of Treace Medical Concepts' stock, indicating strong institutional interest and investment in the company.
• In the latest quarterly earnings report, Treace Medical Concepts reported a loss of ($0.28) earnings per share, exceeding the consensus estimate by $0.01, while also forecasting a negative EPS of -0.92 for FY 2025.

Treace Medical Concepts, Inc. (NASDAQ:TMCI - Get Free Report) has received an average rating of "Hold" from the six analysts that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $9.8333.

Several analysts recently issued reports on the stock. Stifel Nicolaus reduced their price objective on shares of Treace Medical Concepts from $9.00 to $6.00 and set a "hold" rating on the stock in a report on Friday, August 8th. UBS Group reaffirmed a "neutral" rating and issued a $6.50 target price (down from $8.60) on shares of Treace Medical Concepts in a research report on Friday, August 8th.

Treace Medical Concepts Trading Down 0.8%

TMCI traded down $0.06 on Tuesday, hitting $7.34. The company had a trading volume of 205,493 shares, compared to its average volume of 408,012. The firm has a market cap of $463.67 million, a P/E ratio of -9.29 and a beta of 0.71. Treace Medical Concepts has a 1 year low of $4.54 and a 1 year high of $10.79. The company's fifty day moving average price is $6.22 and its 200 day moving average price is $6.96. The company has a current ratio of 3.52, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. The firm had revenue of $47.39 million for the quarter, compared to analyst estimates of $47.08 million. Treace Medical Concepts had a negative net margin of 23.01% and a negative return on equity of 46.76%. Treace Medical Concepts has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Treace Medical Concepts will post -0.92 earnings per share for the current year.

Hedge Funds Weigh In On Treace Medical Concepts

Institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its position in Treace Medical Concepts by 1.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 244,800 shares of the company's stock valued at $2,054,000 after acquiring an additional 2,645 shares in the last quarter. Rhumbline Advisers grew its position in Treace Medical Concepts by 5.8% in the 1st quarter. Rhumbline Advisers now owns 69,916 shares of the company's stock valued at $587,000 after acquiring an additional 3,843 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in Treace Medical Concepts in the 1st quarter valued at about $2,116,000. Arcadia Wealth Management Inc. acquired a new position in Treace Medical Concepts in the 1st quarter valued at about $1,762,000. Finally, Nuveen Asset Management LLC grew its position in Treace Medical Concepts by 11.4% in the 4th quarter. Nuveen Asset Management LLC now owns 472,840 shares of the company's stock valued at $3,518,000 after acquiring an additional 48,525 shares in the last quarter. 84.08% of the stock is owned by institutional investors and hedge funds.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.